137 related articles for article (PubMed ID: 30362665)
21. KRAS and BRAF mutations in serum exosomes from patients with colorectal cancer in a Chinese population.
Hao YX; Li YM; Ye M; Guo YY; Li QW; Peng XM; Wang Q; Zhang SF; Zhao HX; Zhang H; Li GH; Zhu JH; Xiao WH
Oncol Lett; 2017 May; 13(5):3608-3616. PubMed ID: 28521461
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-425-5p Expression Affects BRAF/RAS/MAPK Pathways In Colorectal Cancers.
Angius A; Pira G; Scanu AM; Uva P; Sotgiu G; Saderi L; Manca A; Serra C; Uleri E; Piu C; Caocci M; Ibba G; Zinellu A; Cesaraccio MR; Sanges F; Muroni MR; Dolei A; Cossu-Rocca P; De Miglio MR
Int J Med Sci; 2019; 16(11):1480-1491. PubMed ID: 31673240
[TBL] [Abstract][Full Text] [Related]
23. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
[TBL] [Abstract][Full Text] [Related]
24. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
25. Targeting mutated GTPase KRAS in tumor therapies.
Fan G; Lou L; Song Z; Zhang X; Xiong XF
Eur J Med Chem; 2021 Dec; 226():113816. PubMed ID: 34520956
[TBL] [Abstract][Full Text] [Related]
26. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
[TBL] [Abstract][Full Text] [Related]
27. In Colorectal Cancer Cells With Mutant KRAS, SLC25A22-Mediated Glutaminolysis Reduces DNA Demethylation to Increase WNT Signaling, Stemness, and Drug Resistance.
Wong CC; Xu J; Bian X; Wu JL; Kang W; Qian Y; Li W; Chen H; Gou H; Liu D; Yat Luk ST; Zhou Q; Ji F; Chan LS; Shirasawa S; Sung JJ; Yu J
Gastroenterology; 2020 Dec; 159(6):2163-2180.e6. PubMed ID: 32814111
[TBL] [Abstract][Full Text] [Related]
28. New strategies for targeting glucose metabolism-mediated acidosis for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2018 Jan; 234(1):348-368. PubMed ID: 30069931
[TBL] [Abstract][Full Text] [Related]
29. The potential of PIK3CA, KRAS, BRAF, and APC hotspot mutations as a non-invasive detection method for colorectal cancer.
Alizadeh-Sedigh M; Mahmoodzadeh H; Fazeli MS; Haddadi-Aghdam M; Teimoori-Toolabi L
Mol Cell Probes; 2022 Jun; 63():101807. PubMed ID: 35296442
[TBL] [Abstract][Full Text] [Related]
30. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
31. Targeting the PI3K signaling pathway in KRAS mutant colon cancer.
Hong S; Kim S; Kim HY; Kang M; Jang HH; Lee WS
Cancer Med; 2016 Feb; 5(2):248-55. PubMed ID: 26715098
[TBL] [Abstract][Full Text] [Related]
32. Active Compound of
Song J; Seo H; Kim MR; Lee SJ; Ahn S; Song M
Molecules; 2020 Jun; 25(12):. PubMed ID: 32580297
[TBL] [Abstract][Full Text] [Related]
33. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography.
Achmad A; Hanaoka H; Yoshioka H; Yamamoto S; Tominaga H; Araki T; Ohshima Y; Oriuchi N; Endo K
Cancer Sci; 2012 Mar; 103(3):600-5. PubMed ID: 22126621
[TBL] [Abstract][Full Text] [Related]
34. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
Osumi H; Shinozaki E; Osako M; Kawazoe Y; Oba M; Misaka T; Goto T; Kamo H; Suenaga M; Kumekawa Y; Ogura M; Ozaka M; Matsusaka S; Chin K; Hatake K; Mizunuma N
Mol Clin Oncol; 2015 Sep; 3(5):1053-1057. PubMed ID: 26623049
[TBL] [Abstract][Full Text] [Related]
35. Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.
Taly V; Pekin D; Benhaim L; Kotsopoulos SK; Le Corre D; Li X; Atochin I; Link DR; Griffiths AD; Pallier K; Blons H; Bouché O; Landi B; Hutchison JB; Laurent-Puig P
Clin Chem; 2013 Dec; 59(12):1722-31. PubMed ID: 23938455
[TBL] [Abstract][Full Text] [Related]
36. Colorectal cancer-derived exosomes and modulation KRAS signaling.
Wan YH; Liu QS; Wan SS; Wang RW
Clin Transl Oncol; 2022 Nov; 24(11):2074-2080. PubMed ID: 35789981
[TBL] [Abstract][Full Text] [Related]
37. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.
Knickelbein K; Zhang L
Genes Dis; 2015 Mar; 2(1):4-12. PubMed ID: 25815366
[TBL] [Abstract][Full Text] [Related]
38. Targeting the RAS-dependent chemoresistance: The Warburg connection.
Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
[TBL] [Abstract][Full Text] [Related]
39. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.
Lin Z; Liu Y; Cai S; Yang C; Zhou L; Li W
Technol Cancer Res Treat; 2021; 20():15330338211039131. PubMed ID: 34669528
[No Abstract] [Full Text] [Related]
40. Targeting
Mustachio LM; Chelariu-Raicu A; Szekvolgyi L; Roszik J
Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33801965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]